Arvinas (ARVN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.97, -2.65% vs the prior close of $7.16.
- Volume 760.77K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ARVN dips 2.7% to $6.97. Closed at $6.97, -2.65% vs the prior close of $7.16. Day range $6.93–$7.30, opened at $7.16.
ARVN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ARVN dips 2.7% to $6.97
- Closed at $6.97, -2.65% vs the prior close of $7.16. Day range $6.93–$7.30, opened at $7.16.
- Volume was 760.77K shares, 1.0x its 50-day average of 784.37K.
- Price is -17.1% vs its 50-day average ($8.40) and -29.6% vs its 200-day average ($9.91).
- 52-week range $6.74–$14.51; today's close sits at 3% of that range, 52.0% below the 52-week high.
Oct 15, 2026 — ARVN jumps 5.0% to $7.16
- Closed at $7.16, +4.99% vs the prior close of $6.82. Day range $6.83–$7.18, opened at $6.88.
- Volume was 605.90K shares, 0.8x its 50-day average of 803.68K.
- Price is -15.1% vs its 50-day average ($8.44) and -27.9% vs its 200-day average ($9.93).
- 52-week range $6.74–$14.51; today's close sits at 5% of that range, 50.7% below the 52-week high.
Oct 14, 2026 — ARVN ends flat (-0.3%) to $6.82, a 52-week low, 3 down days in a row
- Closed at $6.82, -0.29% vs the prior close of $6.84. Day range $6.74–$6.96, opened at $6.77.
- Volume was 857.00K shares, 1.0x its 50-day average of 847.20K.
- Price is -19.4% vs its 50-day average ($8.46) and -31.5% vs its 200-day average ($9.95).
- 52-week range $6.74–$14.51; today's close sits at 1% of that range, 53.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ARVN slides 8.2% to $6.84, a 52-week low
- Closed at $6.84, -8.19% vs the prior close of $7.45. Day range $6.80–$7.54, opened at $7.54.
- Volume was 852.90K shares, 1.0x its 50-day average of 844.48K.
- Price is -19.6% vs its 50-day average ($8.51) and -31.5% vs its 200-day average ($9.98).
- 52-week range $6.80–$14.51; today's close sits at 1% of that range, 52.9% below the 52-week high.
Oct 12, 2026 — ARVN dips 2.5% to $7.45
- Closed at $7.45, -2.49% vs the prior close of $7.64. Day range $7.44–$7.73, opened at $7.73.
- Volume was 502.60K shares, 0.6x its 50-day average of 848.18K — lighter than usual.
- Price is -12.7% vs its 50-day average ($8.53) and -25.6% vs its 200-day average ($10.01).
- 52-week range $6.97–$14.51; today's close sits at 6% of that range, 48.7% below the 52-week high.
Oct 9, 2026 — ARVN rises 1.7% to $7.64, 3 up days in a row
- Closed at $7.64, +1.73% vs the prior close of $7.51. Day range $7.46–$7.74, opened at $7.46.
- Volume was 560.00K shares, 0.7x its 50-day average of 847.98K.
- Price is -10.6% vs its 50-day average ($8.54) and -23.8% vs its 200-day average ($10.03).
- 52-week range $6.97–$14.51; today's close sits at 9% of that range, 47.3% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — ARVN rises 0.8% to $7.51
- Closed at $7.51, +0.81% vs the prior close of $7.45. Day range $7.25–$7.55, opened at $7.37.
- Volume was 1.02M shares, 1.2x its 50-day average of 842.46K.
- Price is -12.2% vs its 50-day average ($8.56) and -25.3% vs its 200-day average ($10.05).
- 52-week range $6.97–$14.51; today's close sits at 7% of that range, 48.2% below the 52-week high.
Oct 7, 2026 — ARVN rises 1.9% to $7.45
- Closed at $7.45, +1.92% vs the prior close of $7.31. Day range $7.22–$7.46, opened at $7.25.
- Volume was 601.80K shares, 0.7x its 50-day average of 841.46K.
- Price is -13.1% vs its 50-day average ($8.57) and -26.1% vs its 200-day average ($10.07).
- 52-week range $6.97–$14.51; today's close sits at 6% of that range, 48.7% below the 52-week high.
Oct 6, 2026 — ARVN dips 2.0% to $7.31, a 3-month low
- Closed at $7.31, -2.01% vs the prior close of $7.46. Day range $7.28–$7.49, opened at $7.49.
- Volume was 582.60K shares, 0.7x its 50-day average of 839.32K.
- Price is -14.9% vs its 50-day average ($8.59) and -27.6% vs its 200-day average ($10.09).
- 52-week range $6.97–$14.51; today's close sits at 5% of that range, 49.6% below the 52-week high.
Oct 5, 2026 — ARVN rises 0.7% to $7.46
- Closed at $7.46, +0.67% vs the prior close of $7.41. Day range $7.22–$7.51, opened at $7.46.
- Volume was 627.40K shares, 0.8x its 50-day average of 834.48K.
- Price is -13.3% vs its 50-day average ($8.60) and -26.3% vs its 200-day average ($10.12).
- 52-week range $6.97–$14.51; today's close sits at 6% of that range, 48.6% below the 52-week high.
Oct 2, 2026 — ARVN ends flat (-0.3%) to $7.41, a 3-month low
- Closed at $7.41, -0.27% vs the prior close of $7.43. Day range $7.30–$7.52, opened at $7.51.
- Volume was 585.10K shares, 0.7x its 50-day average of 836.88K.
- Price is -14.0% vs its 50-day average ($8.61) and -26.9% vs its 200-day average ($10.14).
- 52-week range $6.97–$14.51; today's close sits at 6% of that range, 48.9% below the 52-week high.
ARVN latest news & SEC filings
Every SEC filing by or about ARVN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 22, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 31, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $249.70M (prior year $22.40M) (+1014.7% vs Jun 30, 2025)
- Net income: $169.40M (prior year -$61.20M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $2.58 (prior year -$0.84) (swung to profit vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 26, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade ARVN
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Feb 24, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.41% (largest 8.2%).
- Liquidity: about 722.34K shares (≈$5.03M) trade per day on average.
- 52-week position: $6.97 vs a range of $6.74–$14.51 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Andrew Saik sold 5,696 shares on Jun 24, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 8-K Jun 25, 2026.
- Share count: 65.39M shares outstanding (Jul 31, 2026), -10.9% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ARVN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.16 | 7.30 | 6.93 | 6.97 | 760.77K |
| Oct 15, 2026 | 6.88 | 7.18 | 6.83 | 7.16 | 605.90K |
| Oct 14, 2026 | 6.77 | 6.96 | 6.74 | 6.82 | 857.00K |
| Oct 13, 2026 | 7.54 | 7.54 | 6.80 | 6.84 | 852.90K |
| Oct 12, 2026 | 7.73 | 7.73 | 7.44 | 7.45 | 502.60K |
| Oct 9, 2026 | 7.46 | 7.74 | 7.46 | 7.64 | 560.00K |
| Oct 8, 2026 | 7.37 | 7.55 | 7.25 | 7.51 | 1.02M |
| Oct 7, 2026 | 7.25 | 7.46 | 7.22 | 7.45 | 601.80K |
| Oct 6, 2026 | 7.49 | 7.49 | 7.28 | 7.31 | 582.60K |
| Oct 5, 2026 | 7.46 | 7.51 | 7.22 | 7.46 | 627.40K |
| Oct 2, 2026 | 7.51 | 7.52 | 7.30 | 7.41 | 585.10K |
| Oct 1, 2026 | 7.74 | 7.82 | 7.43 | 7.43 | 807.20K |
| Sep 30, 2026 | 7.55 | 8.04 | 7.44 | 7.74 | 1.06M |
| Sep 29, 2026 | 7.49 | 7.52 | 7.36 | 7.50 | 496.00K |
| Sep 28, 2026 | 7.54 | 7.57 | 7.38 | 7.51 | 512.10K |
| Sep 25, 2026 | 7.78 | 7.81 | 7.54 | 7.59 | 713.40K |
| Sep 24, 2026 | 7.81 | 7.82 | 7.39 | 7.79 | 1.22M |
| Sep 23, 2026 | 8.60 | 8.64 | 7.82 | 7.83 | 761.30K |
| Sep 22, 2026 | 8.37 | 8.57 | 8.30 | 8.51 | 685.40K |
| Sep 21, 2026 | 8.37 | 8.44 | 8.21 | 8.30 | 639.80K |
About Arvinas
Arvinas (ARVN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW HAVEN, CT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1655759.
ARVN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Linda Bain | Director | Jun 26, 2026 |
| Everett Cunningham | Director | Jun 26, 2026 |
| John G Houston | Director | Mar 2, 2026 |
| Edward Moore Jr. Kennedy | Director | Jun 26, 2026 |
| Briggs Morrison | Director | Jun 26, 2026 |
| Leslie V Norwalk | Director | Jun 26, 2026 |
| Alsup Laurie Smaldone | Director | Jun 26, 2026 |
| Randy Teel | President and CEO | May 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Noah Berkowitz | Chief Medical Officer | May 13, 2026 |
| Angela M Cacace | Chief Scientific Officer | Jun 18, 2026 |
| David K Loomis | VP, Chief Accounting Officer | May 13, 2026 |
| Andrew Saik | Chief Financial Officer | Jun 24, 2026 |
| Randy Teel | President and CEO | May 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 24, 2026 | Andrew Saik | Sale | 5,696 | $8.16 |
| Jun 24, 2026 | Andrew Saik | Sale | 5,696 | $8.16 |
| Jun 24, 2026 | Andrew Saik | Sale | 5,696 | $8.16 |
| Jun 24, 2026 | Andrew Saik | Sale | 5,696 | $8.16 |
| Jun 17, 2026 | Angela M Cacace | Sale | 2,576 | $7.60 |
| Jun 17, 2026 | Angela M Cacace | Sale | 2,576 | $7.60 |
| Jun 17, 2026 | Angela M Cacace | Sale | 2,576 | $7.60 |
| Jun 17, 2026 | Angela M Cacace | Sale | 2,576 | $7.60 |
| May 21, 2026 | Randy Teel | Sale | 2,209 | $9.04 |
| May 21, 2026 | Randy Teel | Sale | 2,209 | $9.04 |
| May 21, 2026 | Randy Teel | Sale | 2,209 | $9.04 |
| May 21, 2026 | Randy Teel | Sale | 2,209 | $9.04 |
| May 11, 2026 | Noah Berkowitz | Sale | 11,108 | $9.94 |
| May 11, 2026 | Noah Berkowitz | Sale | 11,108 | $9.94 |
| May 11, 2026 | Noah Berkowitz | Sale | 11,108 | $9.94 |
ARVN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-80.80M | -1.14 | $-273.80M |
| Dec 31, 2024 | — | $-198.90M | -2.77 | $-259.30M |
| Dec 31, 2023 | — | $-367.30M | -6.62 | $-347.80M |
| Dec 31, 2022 | — | $-282.50M | -5.31 | $-273.50M |
| Dec 31, 2021 | $46.70M | $-191.00M | -3.82 | $559.40M |
Latest balance sheet: total assets $675.10M, total liabilities $112.90M, cash $94.30M (as of Jun 30, 2026).
ARVN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $9.00 |
| May 12, 2026 | 8-K Item 2.02 (results) | $9.57 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $12.37 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $9.57 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $6.43 |
| May 1, 2025 | 8-K Item 2.02 (results) | $7.23 |
| Feb 11, 2025 | 8-K Item 2.02 (results) | $17.68 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $27.66 |
| Jul 30, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ARVN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.